BioNTech and DualityBio team up to develop ADC therapeutics for cancer
Pharmaceutical Technology
APRIL 3, 2023
BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. The agreements also include the manufacturing and commercialisation of the two assets, including DB-1303 and DB-1311, across the globe.
Let's personalize your content